Skip to main content

Advertisement

Table 2. Individual parasite reduction ratios (PRR) and half-life (t½) for 800 mg ferroquine

From: A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

Subject PRR (95 % CI) t½, h (95 % CI)
R101 73 (47–115) 7.75 (7.01–8.66)
R102 140 (99–198) 6.73 (6.29–7.24)
R103 375 (222–634) 5.61 (5.16–6.16)
R104 244 (129–460) 6.05 (5.43–6.84)
R105 250 (116–542) 6.02 (5.29–7.00)
R106+ 78 (60–101) 7.64 (7.21–8.13)
R107 124 (69–220) 6.91 (6.17–7.85)
R108 479 (356–646) 5.39 (5.14–5.66)
  1. + Subject R106 had low levels of parasitaemia for a period of time after 144 h post treatment. Data for analysis were censored at 144 h